On July 12, 2018 NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer (the "Company"), reported its unaudited revenues for the second quarter of 2018 (Press release, Nanobiotix, JUL, 12, View Source [SID1234527674]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Activity and results during the second quarter of 2018
The Company generated €73k during the second quarter of 2018, which is fully in line with the Company’s
expectations. Most of the revenue was generated from services that Nanobiotix crossed-charged to its partners as per its operational activities.
In April, Nanobiotix presented preclinical data showing that NBTXR3 nanoparticles can activate the cGAS-STING
pathway at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2018 in Chicago, Illinois, USA (April
14-18, 2018). These observations support the rationale for using NBTXR3 with radiation therapy in combination with
immunotherapeutic agents and/or STING agonist to transform tumors into an in-situ cancer vaccine.
Nanobiotix also announced that it will cooperate with The University of Texas MD Anderson Cancer Center, Houston
TX, USA, to run immunotherapeutic pre-clinical research in lung cancer, combining NBTXR3 and Nivolumab. This
project with MD Anderson, one of the world’s leading oncological research centers, will provide an unparalleled ability
to develop pre-clinical data using NBTXR3 activated by radiotherapy plus anti-PD1 Nivolumab (murine version of
Opdivo). Nanobiotix reported that it has been selected to enter Euronext’s Tech40 label, recognizing the best performing Tech SMEs listed on Euronext markets.
In May, Nanobiotix announced that it is launching a research collaboration with Weill Cornell Medicine to begin
nonclinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers. The research
collaboration between Weill Cornell Medicine, based in New York City, and Nanobiotix will be conducted over the
course of one year, with the goal of continuing the exploration of the role of NBTXR3 in Immuno-Oncology.
In June, Nanobiotix announced positive phase II/III topline data in Soft Tissue Sarcoma with NBTXR3. The trial achieved its primary endpoint of pathological Complete Response Rate and its secondary endpoint in operability (R0 rate). NBTXR3 demonstrated significant superiority and clinical benefits for patients compared to the standard of care. The safety profile was confirmed. This randomized trial validated the first-in-class mode of action of NBTXR3.
The positive results from this study support and further validate the Company’s European regulatory strategy of the
previously submitted CE marking application in soft tissue sarcoma. The Company will submit the new data as a
supplement to the European Notified Body in a timely manner.
The Company will present the results at an upcoming international medical conference.
The clinical validation of NBTXR3’s physical mode of action in a very heterogeneous and hard-to-treat disease
strengthens the universal profile of the product and confirms the development strategy in multiple indications.
Currently, the Company is evaluating NBTXR3 in seven clinical trials with a focus on head and neck cancers and
Immuno-Oncology programs.